Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 4,12€(+4,04%). Der Median liegt bei 4,12€(+4,04%).
Kaufen | 2 |
Halten | 4 |
Verkaufen | 0 |
Scoring-Modelle
Dividenden-Strategie | 0 / 15 |
HGI-Strategie | 6 / 18 |
Levermann-Strategie | -1 / 13 |
News
Clover Health: Undervalued Turnaround Play With Promising SaaS Potential
Clover Health's revenue rose 8% in Q3 2024, driven by a 7% growth in Medicare Advantage premiums, despite exiting low-margin ACO REACH program. Cost control measures are paying off, with salaries and benefits down 9%, general expenses down 14%, and losses narrowing significantly. Strong cash reserves of $287.9 million and no long-term debt provide a safety net for strategic investments, particularly in the Clover Assistant platform.» Mehr auf seekingalpha.com
Focus On Costs, Regulatory Outlook For Health Insurers In Q4'24 Earnings Season
Most publicly traded US health insurers are forecast to report sequential revenue and earnings declines for the fourth quarter of 2024, according to S&P Global Market Intelligence analysis of sell-side analyst forecasts. Coming off a challenging end to 2024, the upcoming earnings season is an opportunity for managed care companies to focus on 2025 expectations and Medicare Advantage growth, according to J.P. Morgan analyst Lisa Gill. UnitedHealth and Oscar Health are expected to log sequential and year-over-year revenue growth.» Mehr auf seekingalpha.com
Clover Health Reports 27% Growth in Medicare Advantage Membership, Surpassing 100,000 Lives After Strong Annual Election Period
WILMINGTON, Del., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced a 27% year-over-year growth of its Medicare Advantage (MA) membership during the most recent Annual Election Period (AEP). The Company enters 2025 with over 100,000 members, approximately 95% of whom are enrolled in Clover's flagship 4-Star PPO plan.» Mehr auf globenewswire.com
Unternehmenszahlen
(EUR) | Sep. 2024 | |
---|---|---|
Umsatz | 297,21 Mio | 34,73% |
Bruttoeinkommen | 247,83 Mio | 315,74% |
Nettoeinkommen | −8,22 Mio | 79,01% |
EBITDA | −7,58 Mio | 80,38% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 1,98 Mrd€ |
Anzahl Aktien | 501,11 Mio |
52 Wochen-Hoch/Tief | 4,57€ - 0,59€ |
Dividenden | Nein |
Beta | 2,04 |
KGV (PE Ratio) | −21,88 |
KGWV (PEG Ratio) | −0,81 |
KBV (PB Ratio) | 5,84 |
KUV (PS Ratio) | 1,33 |
Unternehmensprofil
Clover Health Investments, Corp. ist als Medicare Advantage-Versicherer in den Vereinigten Staaten tätig. Das Unternehmen bietet über seinen Clover Assistant, eine Softwareplattform, Gesundheitspläne für Medicare-berechtigte Verbraucher an, die von Preferred Provider Organizations und Health Maintenance Organizations betreut werden. Es konzentriert sich auch auf versicherungsfremde Geschäfte. Clover Health Investments, Corp. wurde 2014 gegründet und hat seinen Sitz in Franklin, Tennessee.
Name | Clover Health |
CEO | Andrew Toy |
Sitz | Franklin, tn USA |
Website | |
Industrie | Gesundheitswesen: Anbieter und Dienstleister |
Börsengang | 12.06.2020 |
Mitarbeiter | 552 |
Ticker Symbole
Börse | Symbol |
---|---|
NASDAQ | CLOV |
Frankfurt | 7QD.F |
Düsseldorf | 7QD.DU |
München | 7QD.MU |
Assets entdecken
Shareholder von Clover Health investieren auch in folgende Assets